Literature DB >> 18448750

Lynch syndrome in women less than 50 years of age with endometrial cancer.

Kellie S Matthews1, Jacob M Estes, Michael G Conner, Upender Manne, Jenny M Whitworth, Warner K Huh, Ronald D Alvarez, J Michael Straughn, Mack N Barnes, Rodney P Rocconi.   

Abstract

OBJECTIVE: To estimate the frequency of mismatch repair deficiencies associated with hereditary nonpolyposis colorectal cancer, or Lynch syndrome, in women less than age 50 with endometrial cancer.
METHODS: Consecutive patients less than age 50 diagnosed with endometrial adenocarcinoma were identified. Available pathologic specimens were freshly sliced, and protein expression for MLH1, MSH2, MSH6, and PMS2 was evaluated by immunohistochemistry. Slides were scored on a semiquantitative method with complete absence of any of the four proteins suggesting a deficiency. All results were confirmed by microsatellite instability testing.
RESULTS: Sixty-one pathology specimens were analyzed. Twenty-one (34%) of the tumors had absence of staining of at least one of the four mismatch repair proteins determined by immunohistochemistry and confirmed by microsatellite instability testing. Obese patients were less likely than nonobese patients to have a mismatch repair deficiency (21% versus 59%, respectively). Non-obese patients had a relative risk for a mismatch repair deficiency of 5.5 (95% confidence interval 1.6-19.1; P=.01).
CONCLUSION: Many women diagnosed with endometrial cancer before age 50 will have a mismatch repair deficiency discovered by immunohistochemistry and microsatellite instability testing. A number of young women diagnosed with endometrial cancer will require further genetic testing for mismatch repair mutations. LEVEL OF EVIDENCE: III.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18448750      PMCID: PMC3665081          DOI: 10.1097/AOG.0b013e31817051d9

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  17 in total

Review 1.  Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma.

Authors:  U Manne; R B Myers; C Moron; R B Poczatek; S Dillard; H Weiss; D Brown; S Srivastava; W E Grizzle
Journal:  Int J Cancer       Date:  1997-06-20       Impact factor: 7.396

2.  Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer.

Authors:  P Peltomäki; H F Vasen
Journal:  Gastroenterology       Date:  1997-10       Impact factor: 22.682

3.  Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.

Authors:  Melissa C Southey; Mark A Jenkins; Leeanne Mead; Jonathan Whitty; Melanie Trivett; Andrea A Tesoriero; Letitia D Smith; Kim Jennings; Garry Grubb; Simon G Royce; Michael D Walsh; Melissa A Barker; Joanne P Young; Jeremy R Jass; D James B St John; Finlay A Macrae; Graham G Giles; John L Hopper
Journal:  J Clin Oncol       Date:  2005-08-22       Impact factor: 44.544

Review 4.  Lessons from hereditary colorectal cancer.

Authors:  K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

5.  p53 antigen loss in stored paraffin slides.

Authors:  J Prioleau; S J Schnitt
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

6.  Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome.

Authors:  Karen H Lu; Mai Dinh; Wendy Kohlmann; Patrice Watson; Jane Green; Sapna Syngal; Prathap Bandipalliam; Lee-May Chen; Brian Allen; Peggy Conrad; Jonathan Terdiman; Charlotte Sun; Molly Daniels; Thomas Burke; David M Gershenson; Henry Lynch; Patrick Lynch; Russell R Broaddus
Journal:  Obstet Gynecol       Date:  2005-03       Impact factor: 7.661

7.  Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant.

Authors:  Maran J W Berends; Ying Wu; Rolf H Sijmons; Rob G J Mensink; Tineke van der Sluis; Jannet M Hordijk-Hos; Elisabeth G E de Vries; Harry Hollema; Arend Karrenbeld; Charles H C M Buys; Ate G J van der Zee; Robert M W Hofstra; Jan H Kleibeuker
Journal:  Am J Hum Genet       Date:  2002-01       Impact factor: 11.025

8.  Nuclear accumulation of p53 in colorectal adenocarcinoma: prognostic importance differs with race and location of the tumor.

Authors:  U Manne; H L Weiss; R B Myers; O K Danner; C Moron; S Srivastava; W E Grizzle
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

9.  Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer.

Authors:  T W Jacobs; J E Prioleau; I E Stillman; S J Schnitt
Journal:  J Natl Cancer Inst       Date:  1996-08-07       Impact factor: 13.506

10.  Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis.

Authors:  Maran J W Berends; Ying Wu; Rolf H Sijmons; Tineke van der Sluis; Wietske Boersmavan Ek; Marjolijn J L Ligtenberg; Neeltje J W Arts; Klaske A ten Hoor; Jan H Kleibeuker; Elisabeth G E de Vries; Marian J E Mourits; Harry Hollema; Charles H C M Buys; Robert M W Hofstra; Ate G J van der Zee
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544

View more
  14 in total

1.  Molecular classification and precision therapy of cancer: immune checkpoint inhibitors.

Authors:  Yingyan Yu
Journal:  Front Med       Date:  2017-12-05       Impact factor: 4.592

2.  Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables.

Authors:  Amy S Joehlin-Price; Carmen M Perrino; Julie Stephens; Floor J Backes; Paul J Goodfellow; David E Cohn; Adrian A Suarez
Journal:  Gynecol Oncol       Date:  2014-01-17       Impact factor: 5.482

3.  Role of endometrial cancer abnormal MMR protein in screening Lynch-syndrome families.

Authors:  Qiongxian Long; Yong Peng; Zhirong Tang; Cailiang Wu
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

4.  Comparison of lifestyle, hormonal and medical factors in women with sporadic and Lynch syndrome-associated endometrial cancer: A retrospective case-case study.

Authors:  Mari H Aaltonen; Synnöve Staff; Jukka-Pekka Mecklin; Kirsi Pylvänäinen; Johanna U Mäenpää
Journal:  Mol Clin Oncol       Date:  2017-04-06

Review 5.  Current and emerging trends in Lynch syndrome identification in women with endometrial cancer.

Authors:  Kimberly E Resnick; Heather Hampel; Richard Fishel; David E Cohn
Journal:  Gynecol Oncol       Date:  2009-04-17       Impact factor: 5.482

6.  Clinical and histomolecular endometrial tumor characterization of patients at-risk for Lynch syndrome in South of Brazil.

Authors:  Silvia Liliana Cossio; Patricia Koehler-Santos; Suzana Arenhart Pessini; Heleuza Mónego; Maria Isabel Edelweiss; Luise Meurer; Abdellatif Errami; Jordy Coffa; Hugo Bock; Maria Luiza Saraiva-Pereira; Patricia Ashton-Prolla; João Carlos Prolla
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

7.  Development of an integrated support system for hereditary cancer and its impact on gynecologic services.

Authors:  Mina Morii-Kashima; Hiroshi Tsubamoto; Chika Sato; Mariko Ushioda; Naohiro Tomita; Yasuo Miyoshi; Tomoko Hashimoto-Tamaoki; Kazuo Tamura; Hideaki Sawai; Hiroaki Shibahara
Journal:  Int J Clin Oncol       Date:  2013-12-19       Impact factor: 3.402

8.  Genome profiling of mismatch repair genes in eight types of tumors.

Authors:  Siqi Wang; Gefei Guan; Cunyi Zou; Qing Guo; Wen Cheng; Shuai Shen; Fang Dong; Anhua Wu; Guang Li; Chen Zhu
Journal:  Cell Cycle       Date:  2021-05-09       Impact factor: 4.534

Review 9.  Deficient mismatch repair: Read all about it (Review).

Authors:  Susan Richman
Journal:  Int J Oncol       Date:  2015-08-12       Impact factor: 5.650

10.  Endometrial cancer risk and survival by tumor MMR status.

Authors:  Penelope M Webb; Amanda B Spurdle; Christina M Nagle; Tracy A O'Mara; Yen Tan; Daniel D Buchanan; Andreas Obermair; Penny Blomfield; Michael A Quinn
Journal:  J Gynecol Oncol       Date:  2018-02-23       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.